SGLT2 inhibitors seem to be an example of compounds that can activate the TGF system sustainably, which is one of the explanations for the positive effects of SGLT2 inhibitors in advanced diabetic nephropathy, as they decrease glomerular hyperfiltration by sustainably activating the TGF system. Here, SLC5A2 is linked to diabetic kidney disease.